Hoosier Cancer Research Network’s vision and mission is to form unparalleled relationships between academic, community, pharmaceutical, and biotech partners with the goal of advancing cancer research, education, and patient advocacy.

Our highly qualified team provides comprehensive study management and support, from conception and study design through project completion and publication.
Over the past year, Hoosier Cancer Research Network has continued to increase its standing as a nonprofit contract research organization. HCRN formed new partnerships and strengthened existing relationships; we expanded our capacity to support the demands of genomically driven research; and we completed the monumental task of moving to a new EDC system and training our member sites.

In September 2015, HCRN announced a partnership with the Bladder Cancer Advocacy Network (BCAN) and Paradigm to launch a genomically driven bladder cancer study. This prospective study is the first project of the Bladder Cancer Genomics Consortium (BCGC), a collaboration of BCAN and major medical centers across the United States. HCRN will serve as the coordinating center of the study, which is expected to open in early 2016.

HCRN’s relationship with the Big Ten Cancer Research Consortium remains strong. The consortium’s first study opened in March 2015. Accrual is ahead of schedule, and the trial is expected to complete enrollment this year. Seven additional BTCRC studies are projected to open in 2016.

HCRN doubled its biospecimen storage capacity. We anticipate additional biorepository enhancements in 2016, further expanding the correlative services we provide to our research partners.

I would like to congratulate HCRN’s data team for completing a successful transition to the OnCore EDC system. It is no small task to move a mountain of data — all the more challenging when you are still supporting the day to day demands of clinical research. The team accomplished this work with excellence, giving attention to the needs of our member sites at every step of the process.

As always, we are deeply grateful to those who support the mission of HCRN through generous donations. These gifts support unfunded or under-funded components of HCRN studies, particularly correlative laboratory work. These studies lay the groundwork for deciphering new information that leads researchers to design more precisely targeted clinical trials, yielding better treatment options for our patients.

Christopher A. Fausel, PharmD, MHA, BCOP
Clinical Manager, Oncology Pharmacy
Indiana University School of Medicine
Hoosier Cancer Research Network’s momentum increased strongly over the past year. I am pleased that investigators from many institutions have brought their ideas forward through our Clinical Trial Working Groups. These groups form the backbone of HCRN’s research development pipeline; they are the means by which good ideas are honed into exceptional clinical trials that translate to real benefit to our patients.

We hear from many investigators that HCRN is a refreshing alternative to the cooperative groups — an alternative that quickly moves research ideas to fruition while fostering collaboration and mentorship between today’s leading experts and those who will lead a new generation of investigators.

It is my pleasure to serve as HCRN’s Chief Scientific Officer at a time of tremendous growth for the organization. A few highlights from 2015 include:

- More than 150 investigators from 42 institutions represented in HCRN Clinical Trial Working Groups.
- 7 clinical trial agreements executed.
- 4 abstracts accepted to ASCO 2015.

The HCRN research development pipeline is stronger than ever. At the end of 2015, more than 25 concepts were in development, spanning a variety of cancer types and therapeutic modalities.

In 2016 and beyond, we will continue to develop novel clinical trials that reflect the best of academic and community collaboration — a partnership model that HCRN pioneered more than 30 years ago. Today, we are proud to continue leading the advance as we take on some of the most difficult challenges in cancer research.
was influenced by the fact that my wife is a breast cancer survivor. Going to the infusion room and talking to the other cancer patients that were there and seeing the real-life struggles families go through with cancer treatments, it’s not hard for me to keep in mind that even though my work isn’t directly noticed by or it doesn’t directly impact the patient, it’s a way to make a behind-the-scenes contribution. There are patients out there that are going through real-life struggles while I’m doing my paperwork.

2015 Recipient
Stephen Glick

Regulatory Affairs Specialist,
IU Health Goshen Center for Cancer Care

A continuing education

Stephen Glick plans to use the $3,000 award to attend educational conferences offered by the Society of Clinical Research Associates (SOCRA). “This award will allow me to move forward with these opportunities,” he says. “I look forward to furthering my education!”

About the Award

The Sandra Turner Excellence in Clinical Research Award was established in 2002 by William B. Fisher, MD, through the George and Sarah Jane Fisher Fund to honor the memory of Sandra Turner, the first executive director of Hoosier Cancer Research Network. Recipients exemplify qualities which Sandra Turner possessed, such as sustained professional commitment, contribution to the progress of oncology care, and unflinching compassion.
I don’t think anyone wakes up and says ‘I want to be a regulatory person.’ I think it’s one of those things people discover and then say, ‘this is interesting.’ . . . At the end of the day, our job is to protect the physicians so they can continue to offer cutting-edge treatment to future patients. The reward is knowing I am giving back. It may not be in a way that is completely apparent, but I am facilitating research that is going to change someone’s life in the future.

**2015 Recipient**

**William Ian Towler, MS, CCRP**

Regulatory Manager, Indiana University Melvin and Bren Simon Cancer Center

---

**From Basic Science to Regulatory Affairs**

Ian Towler earned an undergraduate degree in zoology and a master’s in biology. He spent the better part of a decade doing basic bench science, but ultimately joined a startup company. “Our first big client asked all kinds of questions about rules and regulations and how we were meeting those, and none of us had answers,” he recalls. “So I decided I needed to figure that out. I went back to school and got a degree in regulatory affairs. I ended up in an HIV clinical trial group, and from there moved into cancer.”

---

**By the Numbers**

The regulatory team at the IU Simon Cancer Center is responsible for all IRB submissions, FDA IND submissions, and ClinicalTrials.gov submissions. “Last year we opened 118 trials. This year we are on pace to hit 120-125,” he says. “We had over 2,800 submissions last year. Divided among 6 people, it is a huge volume of work. On top of that we currently manage about 38 INDs.”
I grew up in a family of physicians, so I always saw my dad and siblings working very hard, taking care of patients, and making them feel better. As you can imagine, I was little, so it kind of started out as a curiosity: How can they know so much about the human body, and how can they cure them of their illnesses? I was asking questions of my dad: ‘Dad, you’re a doctor. Can’t you treat cancer?’ That curiosity turned into an ambition to go into the field of medicine.

2015 Recipient
Hirva Mamdani, MD
Hematology/Oncology Fellow, Indiana University School of Medicine

About the Research
Dr. Mamdani plans to use the $15,000 award to advance her research in platinum-resistant small-cell lung cancer. “We want to see if DNA repair pathways are overactive in resistant small-cell lung cancer,” she says. “This project will include getting tissue biopsy from patients when they are initially diagnosed and then another tissue sample when the disease has progressed so we can compare the expression of DNA repair proteins in the same patient rather than different groups of patients.”

About the Award
In 2011, William B. Fisher, MD (pictured with Dr. Mamdani) and others generously endowed a new award through the George and Sarah Jane Fisher Fund to challenge the next generation of cancer researchers. The George and Sarah Jane Fisher Young Investigator Award honors Indiana University oncology fellows and faculty members who have made significant contributions to clinical or basic science research in collaboration with Hoosier Cancer Research Network.
When I was an undergraduate, we had just finished sequencing the human genome. It took years to sequence the first time, and now we’re doing things like sequencing entire tumor genomes from a cell block. We now have drugs that might be able to put that information to good use, and I think that’s the stage we’re entering now in oncology. We are beginning to gather this information in a useable manner, and it’s going to be more and more precise in the coming years.

2015 Recipient
John Paul Flores, MD
Hematology/Oncology Fellow,
Tufts Medical Center

About the Research
Dr. Flores will use the $10,000 award to conduct additional correlative testing for the HCRN GU14-202 clinical trial based on new data that came out toward the end of the trial design. Flores is co-investigator of the study, which is testing the safety and toxicity of the investigational drug niraparib in combination with enzalutamide. Learn more about the GU14-202 study at www.hoosiercancer.org/clinical-trials/gu14-202.

About the Award
The late Donald C. “Danny” Danielson established the Danny Danielson Translational Innovation Award in 2013, granted by the Walther Cancer Foundation. The award is given to investigators working in partnership with Hoosier Cancer Research Network to support the correlative components of clinical trial protocols when financial support is not otherwise available.
Honoring Excellence

Terry Hoeppner Patient Advocacy Award

“It is never about one person. It is really about a community, and that is what we have done for bladder cancer — we’ve created this wonderful community that has a voice. Advancing research and finding a cure is key, but equally important is giving so that no one ever feels they are alone, and that people have the support they need to go through this experience with cancer. I am incredibly proud of BCAN; it has been a community effort these past 10 years.

2014 Recipient
Diane Zipursky Quale
President and Co-Founder, Bladder Cancer Advocacy Network (BCAN)

A “Never Quit” Champion
HCRN honored Diane Zipursky Quale with the Terry Hoeppner Patient Advocacy Award in recognition of her long-standing support for cancer research and patient advocacy. Quale has been a champion of the bladder cancer community for more than 10 years. Her story of uncommon determination reflects the characteristic spirit of her late husband, attorney John Quale, and of Coach Hep, two men who “never quit.” BCAN recently celebrated its 10th anniversary.

About the Award
Terry Hoeppner, beloved Indiana University football coach, lost his battle with brain cancer in 2007. Coach Hep was known for his “never quit” attitude and determination to face challenges head-on. To honor his memory, his wife, Jane Hoeppner, created the Terry Hoeppner Patient Advocacy Award. The award honors individuals who embody Coach Hep’s spirit and determination to champion their cause.
BRE09-146

ASCO 2015 Poster Session

Authors: Miller K, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, Silverman P, King MC, Badve SS, Perkins SM.

Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier Cancer Research Network BRE09-146. Accepted as Poster Presentation at General Poster Session at the ASCO Annual Meeting, May 29-June 2, 2015, Chicago IL. J Clin Oncol 33:5s, 2015 (suppl; abstr 1082).

Gabriela Chiorean, MD
University of Washington
School of Medicine

GI05-102

ASCO 2015 Poster Session

Authors: Chiorean EG, Picus J, Breen T, Ansari RH, Harb WA, Burns M, Spittler AJ, Loehrer PJ.

Phase I/II study of everolimus (E) with irinotecan (Iri) and cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Cancer Research Network GI05-102. Accepted as Poster Presentation at General Poster Session at the ASCO Annual Meeting, May 29-June 2, 2015, Chicago IL. J Clin Oncol 33:5s, 2015 (suppl; abstr 3618).

Lawrence Einhorn, MD
Indiana University
School of Medicine

QL12-153

MASCC/ISOO Annual Meeting 2015 Poster Session

Authors: Brames M, Case-Eads S, Hanna N, Fausel C, Breen T, Einhorn LH.

Phase II study of fosaprepitant plus 5HT3 receptor antagonists plus dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: Hoosier Cancer Research Network QL12-153. Accepted for poster presentation at the MASCC/ISOO Annual Meeting on Supportive Care in Cancer, June 25-27, 2015, Copenhagen, Denmark.
Publications & Abstracts

**QL12-153**

**ASCO 2015 Publication-Only Abstract**

**Authors:** Brames MJ, Case-Eads S, Hanna NH, Fausel CA, Breen T, Einhorn LH.


**Lawrence Einhorn, MD**
Indiana University
School of Medicine

---

**GU12-160**

**ASCO 2015 Trial in Progress Poster**


**Noah Hahn, MD**
Johns Hopkins University
School of Medicine

---

**GU09-145**

**Journal Article**


**Sumanta Pal, MD**
City of Hope
Our Member Network

Academic Sites

**ALABAMA**
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

**ARIZONA**
Mayo Clinic Cancer Center, Phoenix

**CALIFORNIA**
- City of Hope, Duarte
- University of California Los Angeles (TRIO), Pasadena
- USC Norris Comprehensive Cancer Center, Los Angeles

**COLORADO**
University of Colorado Cancer Center, Aurora

**FLORIDA**
- University of Florida Health Cancer Center, Gainesville
- University of Miami, Miami

**GEORGIA**
Winship Cancer Institute of Emory University, Atlanta

**ILLINOIS**
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- University of Chicago Medical Center, Chicago

**INDIANA**
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

**KENTUCKY**
University of Louisville, Louisville

**LOUISIANA**
LSU Health Care Center, Houma

**MARYLAND**
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- University of Maryland Greenebaum Cancer Center, Baltimore

**MASSACHUSETTS**
Dana-Farber Cancer Institute, Boston
Tufts Medical Center, Boston

**MICHIGAN**
University of Michigan Comprehensive Cancer Center, Ann Arbor

**MISSOURI**
Washington University School of Medicine / Siteman Cancer Center, St. Louis

**NEW HAMPSHIRE**
Dartmouth-Hitchcock Norris Cotton Cancer Center, Lebanon

**NEW JERSEY**
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
- Rutgers Cancer Institute of New Jersey, New Brunswick

**NEW MEXICO**
University of New Mexico Cancer Center (NMCCA), Albuquerque

**NEW YORK**
- Tisch Cancer Institute at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
- New York University Cancer Institute, New York
- Roswell Park Cancer Institute, Buffalo
- University of Rochester Medical Center, Rochester

**NORTH CAROLINA**
Comprehensive Cancer Center of Wake Forest University, Winston-Salem
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill

**OHIO**
- Cleveland Clinic Taussig Cancer Institute, Cleveland
- The Ohio State University, Columbus
- University of Cincinnati Cancer Institute, Cincinnati
- University Hospitals Seidman Cancer Center, Cleveland

**OREGON**
Oregon Health & Sciences University, Portland

**PENNSYLVANIA**
- Fox Chase Cancer Center, Philadelphia
- Thomas Jefferson University / Sidney Kimmel Cancer Center, Philadelphia
- University of Pennsylvania, Philadelphia

**SOUTH CAROLINA**
Medical University of South Carolina / Hollings Cancer Center, Charleston

**TENNESSEE**
Erlanger Health System, Chattanooga

**TEXAS**
- Baylor College of Medicine - Methodist Breast Center, Houston
- Cancer Therapy & Research Center at UT Health Science Center, San Antonio
- MD Anderson Cancer Center, Houston
- UT Medical Branch at Galveston, Galveston

**UTAH**
Huntsman Cancer Institute at the University of Utah, Salt Lake City

**VIRGINIA**
University of Virginia Cancer Center, Charlottesville

**WASHINGTON**
University of Washington, Seattle

**WASHINGTON, D.C.**
Georgetown University Medical Center

**WISCONSIN**
- Froedtert & the Medical College of Wisconsin, Milwaukee
- University of Wisconsin Carbone Cancer Center, Madison

**CANADA**
- Cancer Care Manitoba, Winnipeg
- Centre Hospitalier de l’Université de Montréal, Montréal
Our Member Network

Community Sites

**ARIZONA**
Yuma Regional Cancer Center, LLC, Yuma

**ARKANSAS**
Genesis Cancer Center, Hot Springs

**CALIFORNIA**
Marin Specialty Care, Greenbrae
Prostate Oncology Specialists, Inc., Marina Del Rey

**FLORIDA**
Memorial Breast Cancer Center at Memorial Regional Hospital, Hollywood
UF Health Cancer Center at Orlando Health, Orlando

**ILLINOIS**
Illinois Cancer Care, PC, Galesburg
Oncology Specialists, S.C., Niles

**INDIANA**
Community Healthcare - Primary Care Oncology, Munster
Community Regional Cancer Centers, Indianapolis
Floyd Memorial Cancer Center of Indiana, New Albany
Fort Wayne Medical Oncology & Hematology, Fort Wayne
Good Samaritan Hospital, Vincennes
Hope Center, Terre Haute
Horizon Oncology Research, Inc., Lafayette
IU Health Arnett Cancer Centers, Lafayette
IU Health Ball Memorial Hospital Cancer Center, Muncie
IU Health Cancer Centers Bloomington, Bloomington
IU Health Central Indiana Cancer Centers, Indianapolis
IU Health Goshen Center for Cancer Care, Goshen
Jasper Memorial Hospital, Jasper
Kosciusko Community Hospital Cancer Care Center, Warsaw
Northern Indiana Cancer Research Consortium, Inc., South Bend
Oncology Hematology Associates of Southwest Indiana, Newburgh
Radiation Oncology Associates, Fort Wayne
St.Vincent Health, Indianapolis
Union Hospital, Inc., Terre Haute

**KANSAS**
Cancer Center of Kansas, Wichita

**MARYLAND**
Meritus Center for Clinical Research / John R. Marsh Cancer Center, Hagerstown

**MICHIGAN**
The Cancer Center at Metro Health Village, Wyoming

**NEBRASKA**
GU Research Network, LLC, Omaha
Nebraska Methodist Hospital, Omaha

**NEW JERSEY**
Regional Cancer Care Associates, LLC, Cherry Hill
Virtua Fox Chase Cancer Program, Mt. Holly

**OKLAHOMA**
Mercy Clinic Oncology and Hematology - McAuley, Oklahoma City

**OREGON**
Providence Cancer Center, Portland

**PENNSYLVANIA**
Allegheny General Hospital, Pittsburgh
Gettysburg Cancer Center, Gettysburg
PinnacleHealth Cancer Care, Harrisburg

**TENNESSEE**
The Jones Clinic PC, Germantown
The West Clinic, Memphis

**TEXAS**
Joe Arrington Cancer Research and Treatment Center, Lubbock
Medicus Alliance Clinical Research, Houston
Texas Oncology PA, Dallas

**VIRGINIA**
Virginia Oncology Associates, Norfolk

**CANADA**
Virginia Oncology Associates, Norfolk

Learn more about our network and membership advantages at:
hoosiercancer.org/our-network/
Courage to Climb
Columbus North High School
Columbus, Indiana

When Columbus North High School choir director Janie Gordon was diagnosed with breast cancer in 2009, her students wanted to do something to encourage her. They secretly planned a benefit concert in her honor, naming it Courage to Climb, and the concert became an annual event. Since 2011, Columbus North High School students have organized this inspiring annual event, with donations to HCRN exceeding $20,000.

Indiana Department of the VFW Auxiliary

For more than 100 years, the Veterans of Foreign Wars (VFW) Auxiliary has served American veterans and active duty service members through a variety of programs, including Cancer Aid and Research. Each year, state departments receive back a portion of their contribution to the Cancer Aid and Research program, and donate the funds to a research facility. Under the leadership of 2014-2015 president Karen Muston (pictured with HCRN chairman Chris Fausel), the Indiana Department of the VFW Auxiliary raised $97,000 toward the national Cancer Aid and Research program — the fourth largest amount among all state departments — and received back nearly $14,500, which the organization donated to HCRN.

Reps for Research

HCRN Chairman Chris Fausel has once again raised the bar in the fight against cancer. This spring, he reissued his unique challenge to friends and supporters of HCRN: the Reps for Research challenge. Combining his interest in strength training and his passion for investigator-initiated research, Fausel invited pledges for every bench-press “rep” he could complete at the Arnold Sports Festival’s 5K Pump and Run event in Columbus, Ohio. In the two years since it began, Reps for Research has raised nearly $5,000 in donations to HCRN.
Thank you to all who have contributed to Hoosier Cancer Research Network. We are grateful for your commitment of time and resources to help us fulfill our mission. Your generous support strengthens our ability to fund investigator-initiated research. Learn how YOU can contribute to cancer research at www.hoosiercancer.org/make-a-difference/.

Contributions Received in 2015

- John Baute — in memory of William and Marie Wood
- Cynthia Burkhardt — in memory of John Waffle
- Columbus North High School — in honor of Janie Gordon
- Randy Dillinger — in memory of Gerald Dillinger
- Christopher Fausel — in memory of Gerald Fausel
- Nasser Hanna
- HCRN Staff — in memory of Joseph Breen
- LeaEtta Hyer
- Indiana Department of the Veterans of Foreign Wars Auxiliary
- Patrick Kiel
- Patricia Kneebone
- Christopher LeMasters — in memory of Mildred Dobson
- Edward Margolis
- Rakesh Mehta
- Dianna Miller — in memory of June Brune
- Lida Mina
- John Nell
- Bert O’Neil
- James Paris
- Kevin and Nancy Petraits — in memory of Joseph Breen
- Maria Piddoubny — in honor of Elia
- Megan Reimann
- Jessica Roy
- Daniel Rushing
- Hamid Sayar
- Deb and Jim Scahill — in memory of Greg Newland
- Debbie Stockwell
- Lisa Wood — in memory of William Wood

Support Hoosier Cancer Research Network through Amazon Smile

Did you know you can support HCRN through purchases made through Amazon Smile? When you shop, Amazon will donate a portion of your purchase cost to HCRN. Scan the code to the right or visit https://smile.amazon.com/ch/26-0303542 to get started!